Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q4 2015 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$4.50M$4.50Mderived+35.2% vs Q4 2014 Net Income-$15.40M-$15.40MderivedN/M vs Q4 2014 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$139,261N/M Operating Incomederived-$9,926,588N/M Operating Cash Flowderived$2,698,084+36.5% Free Cash Flowderived$2,012,782+35.5% Margins · derivedGross margin3.1%+120.7 pt vs Q4 2014
Operating margin-220.4%+437.0 pt vs Q4 2014
Net margin-341.9%+397.5 pt vs Q4 2014
ended Dec 31, 2015 · filed Mar 30, 2016 · 90 d after period end